Peter Kirk

1.9k total citations · 1 hit paper
14 papers, 1.1k citations indexed

About

Peter Kirk is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Peter Kirk has authored 14 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 8 papers in Immunology and 4 papers in Molecular Biology. Recurrent topics in Peter Kirk's work include CAR-T cell therapy research (7 papers), Immunotherapy and Immune Responses (4 papers) and Signaling Pathways in Disease (3 papers). Peter Kirk is often cited by papers focused on CAR-T cell therapy research (7 papers), Immunotherapy and Immune Responses (4 papers) and Signaling Pathways in Disease (3 papers). Peter Kirk collaborates with scholars based in United Kingdom, United States and Canada. Peter Kirk's co-authors include A. Neil Barclay, Catherine Heddle, Marieangela C. Wilson, Andrew P. Halestrap, Lesley F. Degner, Thomas Hassard, B. Joyce Davison, J. Fernando Bazán, Craig A. Hokanson and Philip A. Lee and has published in prestigious journals such as Journal of Clinical Oncology, The EMBO Journal and Immunity.

In The Last Decade

Peter Kirk

14 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression

2000 576 citations Peter Kirk, Marieangela C. Wilson et al. The EMBO Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Kirk United Kingdom	8	615	281	280	152	132	14	1.1k
Patrick O. Byrne United States	12	553 0.9×	61 0.2×	231 0.8×	39 0.3×	70 0.5×	17	876
Naoya Uchida United States	26	1.2k 1.9×	202 0.7×	258 0.9×	48 0.3×	67 0.5×	89	2.0k
Amanda Harvey United Kingdom	17	615 1.0×	43 0.2×	193 0.7×	126 0.8×	9 0.1×	43	1.0k
Yiping Sun China	19	648 1.1×	379 1.3×	281 1.0×	240 1.6×	19 0.1×	31	1.4k
James P. Koch United States	13	659 1.1×	111 0.4×	281 1.0×	84 0.6×	20 0.2×	19	1.1k
Yingying Jia China	12	2.1k 3.4×	102 0.4×	75 0.3×	221 1.5×	16 0.1×	35	2.4k
Enrique Herrera‐Ceballos Spain	20	128 0.2×	305 1.1×	242 0.9×	14 0.1×	57 0.4×	60	998
Christine Weiß Germany	16	271 0.4×	200 0.7×	102 0.4×	44 0.3×	29 0.2×	27	931

Countries citing papers authored by Peter Kirk

Since Specialization

Citations

This map shows the geographic impact of Peter Kirk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Kirk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Kirk more than expected).

Fields of papers citing papers by Peter Kirk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Kirk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Kirk. The network helps show where Peter Kirk may publish in the future.

Co-authorship network of co-authors of Peter Kirk

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Kirk. A scholar is included among the top collaborators of Peter Kirk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Kirk. Peter Kirk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Sacco, Joseph J., Peter Kirk, Emma Leach, et al.. (2025). Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific. Cell Reports Medicine. 6(4). 102076–102076. 4 indexed citations

Hamid, Omid, Juanita Lopez, Daniel G. Olson, et al.. (2024). Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM).. Journal of Clinical Oncology. 42(16_suppl). 9507–9507. 10 indexed citations

Davar, Diwakar, Juanita Lopez, Daniel G. Olson, et al.. (2024). 694 Phase 1 safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM). Regular and Young Investigator Award Abstracts. A796–A796. 1 indexed citations

Robertson, Ian B., Nele M. G. Dieckmann, Martina Canestraro, et al.. (2023). Tuning the potency and selectivity of ImmTAC molecules by affinity modulation. Clinical & Experimental Immunology. 215(2). 105–119. 9 indexed citations

Davar, Diwakar, Randy F. Sweis, George Blumenschein, et al.. (2021). 91P Phase I dose escalation of IMC-C103C, a CD3×MAGE-A4 T-cell receptor (TCR) bispecific protein. Annals of Oncology. 32. S1411–S1413. 5 indexed citations

Charych, Deborah H., Vidula Dixit, Peter Kirk, et al.. (2017). Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS ONE. 12(7). e0179431–e0179431. 111 indexed citations

Kuo, Peiwen, Mekhala Maiti, Murali K. Addepalli, et al.. (2017). Abstract 1603: NKTR-255 engages the IL-15 pathway driving CD8 T cell survival and CD8 memory T cell proliferation. Cancer Research. 77(13_Supplement). 1603–1603. 6 indexed citations

Rasala, Beth A., Philip A. Lee, Rosa M. F. Cardoso, et al.. (2010). Production of therapeutic proteins in algae, analysis of expression of seven human proteins in the chloroplast of Chlamydomonas reinhardtii. Plant Biotechnology Journal. 8(6). 719–733. 191 indexed citations

Kirk, Peter & J. Fernando Bazán. (2005). Pathogen Recognition: TLRs Throw Us a Curve. Immunity. 23(4). 347–350. 40 indexed citations

10.

Hanna, Suhair, et al.. (2003). A novel form of the membrane protein CD147 that contains an extra Ig-like domain and interacts homophilically. BMC Biochemistry. 4(1). 17–17. 48 indexed citations

11.

Kirk, Peter, et al.. (2000). CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. The EMBO Journal. 19(15). 3896–3904. 576 indexed citations breakdown →

12.

Wilson, Marieangela C., et al.. (1999). Co-localization of immunoglobulin superfamily member CD147 with a monocarboxylate transporter (MCT1). The Journal of Physiology. 58–58. 2 indexed citations

13.

Davison, B. Joyce, Peter Kirk, Lesley F. Degner, & Thomas Hassard. (1999). Information and patient participation in screening for prostate cancer. Patient Education and Counseling. 37(3). 255–263. 119 indexed citations

14.

Kirk, Peter, Mark Filiaggi, R. N. S. Sodhi, & Robert M. Pilliar. (1999). Evaluating sol‐gel ceramic thin films for metal implant applications: III. In vitro aging of sol‐gel‐derived zirconia films on Ti‐6Al‐4V. Journal of Biomedical Materials Research. 48(4). 424–433. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact